envonalkib   Click here for help

GtoPdb Ligand ID: 11874

Synonyms: example 27 [WO2014117718A1]
Compound class: Synthetic organic
Comment: Envonalkib is described as a tyrosine kinase inhibitor and antineoplastic in the WHO proposed INN list 126 (Jan 2022). This chemical structure is claimed in patent WO2014117718A1, which suggests that it is an ALK inhibitor [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 85.53
Molecular weight 505.14
XLogP 5.76
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1cc(ncc1c1cnc(c(c1)O[C@@H](c1c(Cl)ccc(c1Cl)F)C)N)N1CCNC[C@@H]1C
Isomeric SMILES Clc1c(c(ccc1F)Cl)[C@@H](C)Oc1cc(cnc1N)c1cnc(cc1OC)N1[C@H](CNCC1)C
InChI InChI=1S/C24H26Cl2FN5O2/c1-13-10-29-6-7-32(13)21-9-19(33-3)16(12-30-21)15-8-20(24(28)31-11-15)34-14(2)22-17(25)4-5-18(27)23(22)26/h4-5,8-9,11-14,29H,6-7,10H2,1-3H3,(H2,28,31)/t13-,14+/m0/s1
InChI Key BVGDAZBTIVRTGO-UONOGXRCSA-N
References
1. Xiao D, Xu X, Liu X, Yu H, Liu Z, Peng Y, Sun Y, Luo H, Kong F, Han Y et al.. (2014)
Substituted 2-aminopyridine protein kinase inhibitor.
Patent number: WO2014117718A1. Assignee: Centaurus Biopharma Co Ltd, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd. Priority date: 02/02/2013. Publication date: 07/08/2014.